Effects of GLP-1 on liver fat and energy use in obese girls with PCOS
Impact of GLP-1 on Hepatic Fat and Energy Utilization in Obese Girls with Polycystic Ovarian Syndrome
This study is looking at how a medication called GLP-1 receptor agonist can help reduce liver fat and improve energy use in overweight girls with Polycystic Ovary Syndrome (PCOS), aiming to find better treatment options for them.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Colorado Denver NIH-funded |
| Lab location | 1 site (Aurora, UNITED STATES) |
| Project ID | NIH-10692902 on NIH RePORTER |
What this research studies
This research investigates how a medication called GLP-1 receptor agonist (GLP-1 RA) can impact liver fat and energy utilization in obese girls diagnosed with Polycystic Ovary Syndrome (PCOS). The study aims to understand the relationship between GLP-1 levels, insulin resistance, and metabolic complications such as nonalcoholic fatty liver disease (NAFLD) in this population. By administering GLP-1 RA over a longer period, researchers hope to determine its effectiveness in reducing liver fat and improving metabolic health. This research is particularly important as it addresses a significant gap in treatment options for adolescents with PCOS.
Who could benefit from this research
Good fit: Ideal candidates for this research are obese girls aged 12 to 20 who have been diagnosed with Polycystic Ovary Syndrome.
Not a fit: Patients who are not diagnosed with PCOS or are outside the age range of 12 to 20 may not receive any benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapeutic options that improve metabolic health and reduce complications for girls with PCOS.
How similar studies have performed: Previous research in adults has shown that GLP-1 RA can effectively reduce liver fat and improve metabolic parameters, suggesting potential success in this adolescent population.
Where this research is happening
Aurora, UNITED STATES
- University of Colorado Denver — Aurora, United States (Active)
Researchers
- Principal investigator: Cree, Melanie G — University of Colorado Denver
- Study coordinator: Cree, Melanie G
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.